NCIt definition : A preparation composed of ex-vivo expanded CXC chemokine receptor 2 (CXCR2) modified
patient-derived activated CD70 (CD27 ligand; tumor necrosis factor superfamily member
7; TNFSF7) chimeric antigen receptor (CAR) (8R-70CAR) T-cells, with potential immunostimulating
and antineoplastic activities. Upon administration of the autologous CXCR2-modified
CD70 CAR T-cells, the anti-CD70-CARs on the T-cell surfaces target and bind to the
CD70 antigen on tumor cell surfaces. This induces a cytotoxic T-lymphocyte (CTL)-mediated
immune response against CD70-expressing tumor cells. CD70, a cytokine belonging to
the tumor necrosis factor superfamily (TNFSF) and the ligand for the costimulatory
receptor CD27, is expressed on the surfaces of various types of cancer cells; its
overexpression may play an important role in the evasion of immune surveillance. CXCR2,
a transmembrane protein also known as interleukin (IL)-8 receptor B (IL-8RB), plays
a key role in inflammation and cancer progression. Certain CXCR2 ligands, such as
CXCL1 and CXCL8 (IL-8), are expressed by tumor cells. CXCR2-modified CARs enhance
intratumoral T-cell trafficking toward tumor cells and promotes persistence of T-cells.
This may enhance the T-cell-mediated immune response against the CD70-expressing tumor
cells.;